Last reviewed · How we verify
Intravenous infusion of transduced cells
Intravenous infusion of transduced cells is a Biologic drug developed by Great Ormond Street Hospital for Children NHS Foundation Trust. It is currently in Phase 1 development.
At a glance
| Generic name | Intravenous infusion of transduced cells |
|---|---|
| Sponsor | Great Ormond Street Hospital for Children NHS Foundation Trust |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Pyrexia
- Anaemia
- Nausea
- Headache
- Diarrhoea
- Neutropenia
- Fatigue
- Neutrophil count decreased
- Hypotension
- Hypokalaemia
- White blood cell count decreased
- Vomiting
Key clinical trials
- Safety and Efficacy Study of Transplantation of Autologous CD34+ Cells Transduced With the G2ARTE Lentiviral Vector Expressing the DCLRE1C cDNA in Artemis (DCLRE1C) Deficient Severe Combined Immunodeficiency Patients (ARTEGENE) (PHASE1, PHASE2)
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
- CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (PHASE2)
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy (PHASE3)
- Controlling Hyperactive Immunity With Long-lived Lymphocytes (PHASE1, PHASE2)
- A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD) (PHASE2)
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (PHASE1, PHASE2)
- Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous infusion of transduced cells CI brief — competitive landscape report
- Intravenous infusion of transduced cells updates RSS · CI watch RSS
- Great Ormond Street Hospital for Children NHS Foundation Trust portfolio CI
Frequently asked questions about Intravenous infusion of transduced cells
What is Intravenous infusion of transduced cells?
Intravenous infusion of transduced cells is a Biologic drug developed by Great Ormond Street Hospital for Children NHS Foundation Trust.
Who makes Intravenous infusion of transduced cells?
Intravenous infusion of transduced cells is developed by Great Ormond Street Hospital for Children NHS Foundation Trust (see full Great Ormond Street Hospital for Children NHS Foundation Trust pipeline at /company/great-ormond-street-hospital-for-children-nhs-foundation-trust).
What development phase is Intravenous infusion of transduced cells in?
Intravenous infusion of transduced cells is in Phase 1.
What are the side effects of Intravenous infusion of transduced cells?
Common side effects of Intravenous infusion of transduced cells include Pyrexia, Anaemia, Nausea, Headache, Diarrhoea, Neutropenia.